Program
Osilodrostat
Also written as “LCI699” and “osilodrostat”.
Its studies are mostly in Hypertension · Cushing Syndrome · Adrenocortical Hyperfunction · Pituitary ACTH Hypersecretion · Essential Hypertension, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 100 open or running | phase 3since Jun 17, 2014 | Aug 5, 2008 | none ahead |
| RECORDATI GROUP | 32 open or running | phase 4since Nov 19, 2025 | Jul 20, 2018 | Jul 21, 2027phase 2 · NCT03708900 |
Also a collaborator on its studies: great-lakes-drug-development-inc and integrium.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2008First study: phase 2 study in HyperaldosteronismNew to NovartisNovartis · NCT00732771 · 12 enrolled · France
- Sep 23, 2008Phase 2 study in Essential HypertensionNovartis · NCT00758524 · 628 enrolled · United States
- Jan 5, 20092 phase 2 studies in HypertensionNovartis · NCT00817635, NCT00817414
- Apr 6, 2011Phase 2 study in Adrenocortical HyperfunctionNovartis · NCT01331239 · 31 enrolled · United States, France, Italy and more
- Jun 17, 2014Phase 3 study in Adrenocortical HyperfunctionNovartis · NCT02180217 · 137 enrolled · United States, Argentina, Austria and more
- Feb 23, 2015Phase 1 study in Hepatic ImpairmentNovartis · NCT02372084 · 33 enrolled · United States
- Mar 20, 2015Phase 1 study in Renal InsufficiencyNovartis · NCT02399202 · 15 enrolled · Bulgaria, Germany
- Jun 8, 2015Phase 2 study in Cushing SyndromeNovartis · NCT02468193 · 9 enrolled · Japan
- Feb 27, 2016Phase 3 study in Pituitary ACTH HypersecretionNovartis · NCT02697734 · 73 enrolled · United States, Belgium, Brazil and more
- Jul 20, 2018RECORDATI GROUP's first study: phase 2 study in Cushing SyndromeNew to RECORDATI GROUPRECORDATI GROUP · NCT03606408 · 127 enrolled · United States, Argentina, Austria and more
- Oct 8, 2018Phase 2 study in Cushing SyndromeRECORDATI GROUP · NCT03708900 · 12 planned · United States, Belgium, Bulgaria and more
- Nov 19, 2025Phase 4 study in HypertensionRECORDATI GROUP · NCT07247162 · 63 planned · United States
Ahead
- Jul 21, 2027Primary completion: phase 2 study in Cushing SyndromeRECORDATI GROUP · NCT03708900
- May 2028Primary completion: phase 4 study in HypertensionRECORDATI GROUP · NCT07247162
TargetBeta
“An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), ”NCIt, by rule
“Cytochrome P450 11B1 inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07247162Hypertension · United States | 4 | Recruiting | RECORDATI GROUP | May 2028 | 63 |
| NCT03708900Cushing Syndrome · United States, Belgium, Bulgaria and more | 2 | Recruiting | RECORDATI GROUP | Jul 21, 2027 | 12 |
| NCT03606408Cushing Syndrome · United States, Argentina, Austria and more | 2 | Completed | RECORDATI GROUP | Nov 16, 2023 | 127 |
| NCT02697734Pituitary ACTH Hypersecretion · United States, Belgium, Brazil and more | 3 | Completed | Novartis | Jun 19, 2019 | 73 |
| NCT02468193Cushing Syndrome · Japan | 2 | Completed | Novartis | Jun 7, 2018 | 9 |
| NCT02399202Renal Insufficiency · Bulgaria, Germany | 1 | Completed | Novartis | Mar 21, 2016 | 15 |
| NCT02372084Hepatic Impairment · United States | 1 | Completed | Novartis | May 19, 2016 | 33 |
| NCT02180217Adrenocortical Hyperfunction · United States, Argentina, Austria and more | 3 | Completed | Novartis | Feb 21, 2018 | 137 |
| NCT01331239Adrenocortical Hyperfunction · United States, France, Italy and more | 2 | Completed | Novartis | Oct 22, 2019 | 31 |
| NCT00817635Hypertension · United States, Iceland | 2 | Completed | Novartis | Oct 13, 2009 | 155 |
| NCT00817414Hypertension · United States, Iceland | 2 | Completed | Novartis | Aug 12, 2009 | 63 |
| NCT00758524Essential Hypertension · United States | 2 | Completed | Novartis | Jul 2, 2009 | 628 |
| NCT00732771Hyperaldosteronism · France | 2 | Completed | Novartis | May 2009 | 12 |
How it is read
Names in the registry
- “LCI699”, 6 entries
- “osilodrostat”, 5 entries
- “Osilodrostat”, 2 entries
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Cushing Syndrome, 3 studies
- Adrenocortical Hyperfunction, 2 studies
- Pituitary ACTH Hypersecretion, 1 study
- Essential Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.